An open label, dose escalation phase I study of the safety, pharmaccodynamics and pharmacokinetics of ATN-224 capsules in patients with advanced hematological malignancies

Trial Profile

An open label, dose escalation phase I study of the safety, pharmaccodynamics and pharmacokinetics of ATN-224 capsules in patients with advanced hematological malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2006

At a glance

  • Drugs Bis-choline tetrathiomolybdate (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top